Nicotine vaping and conventional tobacco product use among adults in the United States stratified by substance use disorder severity: A cross-sectional analysis
Publication date: 1 November 2026 Source: Drug and Alcohol Dependence, Volume 288 Author(s): Erin Bredenberg, Ingrid A. Binswanger, Susan L. Calcaterra, Angela Keniston, Christine M. Steeger, Gina R. Kruse
Nicotine vaping and conventional tobacco product use among adults in the United States stratified by substance use disorder severity: A cross-sectional analysis. // Drug and Alcohol Dependence. – URL: https://www.sciencedirect.com/science/article/pii/S0376871626003650?dgcid=rss_sd_all
Nicotine vaping and conventional tobacco product use among adults in the United States stratified by substance use disorder severity: A cross-sectional analysis. Drug and Alcohol Dependence. https://www.sciencedirect.com/science/article/pii/S0376871626003650?dgcid=rss_sd_all
“Nicotine vaping and conventional tobacco product use among adults in the United States stratified by substance use disorder severity: A cross-sectional analysis.” Drug and Alcohol Dependence.
@article{article43498,
title = {Nicotine vaping and conventional tobacco product use among adults in the United States stratified by substance use disorder severity: A cross-sectional analysis},
journal = {Drug and Alcohol Dependence},
url = {https://www.sciencedirect.com/science/article/pii/S0376871626003650?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...